These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1622160)

  • 1. Bactericidal titers of loracarbef (LY 163892) in serum and killing rates in volunteers receiving 400 versus 200 milligrams.
    Van der Auwera P
    Antimicrob Agents Chemother; 1992 Mar; 36(3):521-6. PubMed ID: 1622160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic activity of five oral cephalosporins against Haemophilus influenzae.
    Stein GE; Schooley S; Walker RD; Strenkoski-Nix L
    Pharmacotherapy; 1997; 17(2):235-41. PubMed ID: 9085313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of subinhibitory concentrations of loracarbef (LY 163892) and daptomycin (LY 146032) on bacterial phagocytosis, killing and serum sensitivity.
    Tripodi MF; Adinolfi LE; Utili R; Marrone A; Ruggiero G
    J Antimicrob Chemother; 1990 Oct; 26(4):491-501. PubMed ID: 2174852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro activity of cefprozil (BMY 28100) and loracarbef (LY 163892) against pathogens obtained from middle ear fluid.
    Arguedas AG; Arrieta AC; Stutman HR; Akaniro JC; Marks MI
    J Antimicrob Chemother; 1991 Mar; 27(3):311-8. PubMed ID: 1903788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A national collaborative study of the in vitro activity of oral cephalosporins and loracarbef (LY 163892). Australian Group for the Study of Antimicrobial Resistance (AGAR).
    Benn RA; Fernandes CJ; Nimmo GR
    Pathology; 1997 Feb; 29(1):79-83. PubMed ID: 9094185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of loracarbef and effects of susceptibility test methods.
    Doern G
    Am J Med; 1992 Jun; 92(6A):7S-15S. PubMed ID: 1621748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics, tissue penetration and in-vitro activity of loracarbef, a beta-lactam antibiotic of the carbacephem class.
    Lees AS; Andrews JM; Wise R
    J Antimicrob Chemother; 1993 Dec; 32(6):853-9. PubMed ID: 8144425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro study of the post-antibiotic effect and the bactericidal activity of Cefditoren and ten other oral antimicrobial agents against upper and lower respiratory tract pathogens.
    Dubois J; St-Pierre C
    Diagn Microbiol Infect Dis; 2000 Jul; 37(3):187-93. PubMed ID: 10904192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose.
    Wagenlehner FM; Wydra S; Onda H; Kinzig-Schippers M; Sörgel F; Naber KG
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3789-94. PubMed ID: 14638484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model.
    Cappelletty DM; Rybak MJ
    Antimicrob Agents Chemother; 1996 May; 40(5):1148-52. PubMed ID: 8723456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhibiting an N526K mutation in the ftsI gene.
    Torrico M; Aguilar L; González N; Giménez MJ; Echeverría O; Cafini F; Sevillano D; Alou L; Coronel P; Prieto J
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3699-706. PubMed ID: 17664320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of cefdinir against respiratory pathogens isolated in Sicily with reference to beta-lactamase production.
    Blandino G; Aleo G; Caccamo F; Nicolosi VM; Siracusa V; Speciale A
    J Chemother; 1996 Jun; 8(3):193-9. PubMed ID: 8808715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative activity of cefodizime and ceftriaxone against respiratory pathogens in an in vitro pharmacodynamic model simulating concentration-time curves.
    Blandino G; Milazzo I; Musumeci R; Nicolosi VM; Speciale A; Nicoletti G
    J Chemother; 2000 Dec; 12(6):503-8. PubMed ID: 11154034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Third generation oral cephalosporins: comparative in vitro kinetics.
    Speciale A; Blandino G; Nicoletti G
    J Chemother; 1995 May; 7 Suppl 1():9-12. PubMed ID: 8618112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotic susceptibility of upper respiratory tract pathogens in Sweden: a seven year follow-up study including loracarbef. Swedish Respiratory Tract Study Group.
    Olsson-Liljequist B; Burman LG; Kallings I
    Scand J Infect Dis; 1992; 24(4):485-93. PubMed ID: 1411315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of loracarbef (LY163892), a new oral carbacephem antimicrobial agent, against respiratory isolates of Haemophilus influenzae and Moraxella catarrhalis.
    Doern GV; Vautour R; Parker D; Tubert T; Torres B
    Antimicrob Agents Chemother; 1991 Jul; 35(7):1504-7. PubMed ID: 1929318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of cefprozil (BMY 28100) and cefepime (BMY 28142) against Streptococcus pneumoniae, Branhamella catarrhalis, and Haemophilus influenzae, and provisional interpretive criteria for disk diffusion and dilution susceptibility tests with Haemophilus influenzae.
    Doern GV; Vautour R
    Diagn Microbiol Infect Dis; 1992; 15(7):633-40. PubMed ID: 1424521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loracarbef. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.
    Brogden RN; McTavish D
    Drugs; 1993 May; 45(5):716-36. PubMed ID: 7686466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of ceftriaxone and cefixime against community-acquired respiratory tract pathogens.
    Owens RC; Tessier P; Nightingale CH; Ambrose PG; Quintiliani R; Nicolau DP
    Int J Antimicrob Agents; 2001 Jun; 17(6):483-9. PubMed ID: 11397619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species.
    Johnson DM; Biedenbach DJ; Beach ML; Pfaller MA; Jones RN
    Diagn Microbiol Infect Dis; 2000 Jun; 37(2):99-105. PubMed ID: 10863104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.